Rheumatoid Arthritis is under clinical development by NovelMed Therapeutics and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rheumatoid Arthritis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rheumatoid Arthritis overview

The therapeutic candidate is under development for the treatment of rheumatoid arthritis (RA). It is being developed based on humanized antibody platform and targets the alternative pathway’s key proteins and prevents inflammation.

NovelMed Therapeutics overview

NovelMed Therapeutics (NovelMed) is a biotechnology company. The company develops transformative therapies for the treatment of orphan and non-orphan diseases. It offers monoclonal antibodies in the therapeutic areas of paroxysmal nocturnal hemoglobinuria, age related macular degeneration, osteoarthritis, ischemia, arthritis and chronic kidney diseases, among others. NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures. It also conducts research and development for complement-mediated diseases. The company caters to patients, healthcare providers, employees, and investors across the US. NovelMed is headquartered in Cleveland, Ohio, the US.

For a complete picture of Rheumatoid Arthritis’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.